Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume 32, Issue 16, Pages 1968-1976
Publisher
Oxford University Press (OUP)
Online
2011-03-19
DOI
10.1093/eurheartj/ehr052
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) James V. Freeman et al. ANNALS OF INTERNAL MEDICINE
- Dabigatran Versus Warfarin in Patients With Atrial Fibrillation
- (2011) Rangadham Nagarakanti et al. CIRCULATION
- Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
- (2010) Christian T. Ruff et al. AMERICAN HEART JOURNAL
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
- (2010) Renato D. Lopes et al. AMERICAN HEART JOURNAL
- Rivaroxaban: A New Oral Factor Xa Inhibitor
- (2010) Elisabeth Perzborn et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
- (2010) et al. EUROPACE
- Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors
- (2010) Jan Steffel et al. Journal of Cardiovascular Medicine
- Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
- (2010) Koichiro Ogata et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion
- (2010) I. PATY et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
- (2010) A. HILLARP et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
- (2010) Lars Wallentin et al. LANCET
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
- (2010) Michael Rud Lassen et al. LANCET
- Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
- (2010) Hans-Christoph Diener et al. LANCET NEUROLOGY
- Newly Identified Events in the RE-LY Trial
- (2010) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Rivaroxaban for Symptomatic Venous Thromboembolism
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
- (2010) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assays for Measuring Rivaroxaban: Their Suitability and Limitations
- (2010) Edelgard Lindhoff-Last et al. THERAPEUTIC DRUG MONITORING
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
- (2010) Zhaoqing Wang et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
- (2010) Joachim Stangier et al. THROMBOSIS AND HAEMOSTASIS
- Apixaban versus enoxaparin in patients with total knee arthroplasty
- (2010) Jiahao Huang et al. THROMBOSIS AND HAEMOSTASIS
- Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
- (2010) Fariba Baghaei et al. THROMBOSIS AND HAEMOSTASIS
- Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
- (2010) Michael Rud Lassen et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
- (2010) R.J. Friedman et al. THROMBOSIS RESEARCH
- Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome
- (2009) CIRCULATION
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
- (2009) JL Mega et al. LANCET
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
- (2009) Alexander GG Turpie et al. LANCET
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
- (2009) Sam Schulman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
- (2009) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Laboratory Monitoring of Anticoagulation: Where Do We Stand?
- (2009) Armando Tripodi et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Antithrombotic and Thrombolytic Therapy
- (2008) Jack Hirsh et al. CHEST
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate
- (2008) Joachim Stangier CLINICAL PHARMACOKINETICS
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
- (2008) N. Raghavan et al. DRUG METABOLISM AND DISPOSITION
- Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders
- (2008) Paolo Prandoni et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
- (2008) JOURNAL OF ARTHROPLASTY
- Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies
- (2008) P. C. WONG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
- (2008) et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
- (2008) Ajay K Kakkar et al. LANCET
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
- (2008) Bengt I. Eriksson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
- (2008) Michael R. Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
- (2008) David J. Gladstone et al. STROKE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now